Clinical Trials Logo

Agammaglobulinemia, BTK clinical trials

View clinical trials related to Agammaglobulinemia, BTK.

Filter by:
  • None
  • Page 1

NCT ID: NCT02234791 Not yet recruiting - Clinical trials for Agammaglobulinemia, BTK

Mutation of the BTK Gene and Genotype-phenotype Correlation of Chinese Patients With X-Linked Agammaglobulinemia

Start date: September 2014
Phase: N/A
Study type: Observational [Patient Registry]

X-linked agammaglobulinemia (XLA) is a humoral primary immunodeficiency in which affected patients have very low levels of peripheral B cells and a profound deficiency of all immunoglobulin isotypes. Mutations in the gene encoding for Bruton's tyrosine kinase (Btk) are responsible for most of the gammaglobulinemia. We tend to investigate the gene mutation and clinical features of Chinese X-linked agammaglobulinemia (XLA) patients, and also examined the relationship between specific Btk gene mutations and severity of clinical presentation.